The Arizona State Retirement System has an equity position of $ 344,000 in Vericel Co. (NASDAQ: VCEL). “IMS

The Arizona State Retirement System cut its stake in Vericel Co. (NASDAQ: VCEL) by 8.6% in the fourth quarter, the company said in its most recent disclosure to the Securities and Exchange Commission. The fund owned 140 shares of the biotechnology company shares after selling 1 49 shares during the period. The Arizona State Retirement System’s stakes in Vericel were worth $ 344 as of its last filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have recently changed their holdings in VCEL. The Swiss National Bank increased its stake in Vericel by 1.6% in the third quarter. The Swiss National Bank now owns 91,700 shares in the biotechnology company valued at $ 1,699, after purchasing an additional 1,344 shares in the last quarter. Zürcher Kantonalbank Zürcher Kantonalbank increased its stake in Vericel shares by 25.0% in the fourth quarter. Zürcher Kantonalbank Zürcher Kantonalbank now owns 6,989 shares in the biotechnology company, valued at $ 191, after purchasing an additional 1,531 shares last quarter. Nisa Investment Advisors LLC increased its stake in Vericel by 3% 191 in the fourth quarter. Nisa Investment Advisors LLC now owns 2,595 shares in the biotechnology company, valued at $ 785, after purchasing an additional 1,950 shares last quarter. Jane Street Group LLC increased its stake in Vericel. 4% in the 3rd quarter. Jane Street Group LLC now owns 12,785 shares in the biotechnology company, valued at $ 422, after purchasing an additional 2,142 shares last quarter. Finally, the California Public Employees Retirement System added 2.5% to its position in Vericel stock in the third quarter. The California Public Employees Retirement System now owns 91,300 shares in the biotechnology company, valued at $ 1,729, after acquiring an additional 2,300 shares during the period. Hedge funds and other institutional investors own 91% of the company’s stock.

See Also:  Turpentine Oil Market Analysis 2021, Growth by Top Companies, Trends by Type and Application, Forecast Analysis to 2026 - Baden Wurttemberg Zeitung

Several analysts recently rated the VCEL share. HC Wainwright raised its price target for Vericel from $ 10th to $ 44th and gave the stock a “buy” rating in a research report on Tuesday, January 00th. Truist raised his target price on Vericel from $ 28th to $ 60th in a research report on Tuesday, February 10th. LADENBURG THALM / SH SH raised its target price for Vericel from $ 19.44 to $ 34 and gave the stock a buy rating in a research note on Tuesday, January 1st. BTIG Research raised its target price on Vericel from $ 19 to $. and gave the stock a buy rating in a report on Monday, January, 000th. Finally, Zacks Investment Research upgraded Vericel from a “Hold” rating to a “Buy” rating and a $. Price target in a report on Thursday, January

th. Two research analysts for stocks have given the stock a hold rating and seven a buy rating. The stock currently has an average rating of “Buy” and a consensus price target of $ 78. 45.

NASDAQ VCEL opens at $ 50. 28 Mondays. The company’s 50-day moving average price is $ 33,41 and its 172- day moving price is $ 19,000. The stock has a market cap of $ 2. 26 billion, a value for money of -5, 80,. and a beta of 3.. Vericel Co. has a 1-year low of $ 6 53 and a 1-year high of $ 46.78.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and markets cell therapies for the sports medicine and severe burn markets in the United States. It markets autologous cell therapy products that include MACI, an autologous cellularized scaffold product for repairing symptomatic and single or multiple cartilage defects of the full thickness knee; and Epicel, a permanent humanitarian skin substitute application used to treat patients with deep or full-thickness skin burns.

See Also:  Arizona House of Representatives committee passes unemployment bill, now moving to House for vote

Special Story: What Does the Dow Jones Industrial Average (DJIA) Measure?

Receive News and Reviews for Vericel Daily – Enter your email address below to receive a brief daily summary of breaking news and analysts’ ratings for Vericel and related companies with IMS Magazine’s FREE daily email newsletter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.